Samsung Bioepis Discusses Interchangeability And Adalimumab
Regulatory Chief Voices Support For Making All FDA-Approved Biosimilars Interchangeable
Executive Summary
As Samsung Bioepis seeks a US interchangeability designation for its Organon-partnered Hadlima adalimumab biosimilar, the firm’s regulatory affairs chief Byoungin Jung talks to Generics Bulletin about the significance of interchangeability for US biosimilars – and the firm’s support for legislative efforts to have all US approved biosimilars automatically designated as interchangeable.